Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Impact Report 2018

At The Kids Research Institute Australia, our vision is simple - happy healthy kids. We bring together community, researchers, practitioners, policy makers and funders who share our mission to improve the health, development and lives of children and young people through excellence in research.

Annual Report 2014

The Kids Research Institute Australia's annual report highlights the accomplishments of our researchers, furthering our mission to secure a happier, healthier future for kids everywhere.

Annual Report 2009

The Kids Research Institute Australia's annual report highlights the accomplishments of our researchers, furthering our mission to secure a happier, healthier future for kids everywhere.

Research

Adult psychosocial outcomes of children with specific language impairment, pragmatic language impairment and autism

Evidence that some children also develop autistic symptomatology over time has raised suggestions that developmental language disorder...

Research

Investigating genotype-phenotype relationships in Rett syndrome using an international data set

This study uses data from a large international database, InterRett, to examine genotype-phenotype relationships and compares these with previous findings in...

Research

The common BDNF polymorphism may be a modifier of disease severity in Rett syndrome

Rett syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-binding protein 2 (MECP2).

Research

Siblings of children with disabilities: challenges and opportunities

Siblings of children with disabilities: challenges and opportunities

Research

Investigations into the role of ST2 in acute asthma in children

This study investigated the potential role of ST2 in children with acute asthma.

Research

Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy

Topical application of tumors with the TLR7 agonist imiquimod is an effective adjunct treatment for a range of primary dermatological cancers.